Tenax Therapeutics (TENX) AI Stock Analysis

• Market Cap: $25.35M
• Dividend Yield: N/A
• Average Volume (3M): 34.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.09
• Revenue Growth: N/A
• EPS Growth: 84.17%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 4,148,495
• 10 Day Avg. Volume: 21,765
• 30 Day Avg. Volume: 34,322
• PEG Ratio: -0.20
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.47
• Enterprise Value/Market Cap: -3.42
• Enterprise Value/Revenue: -7.49K
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 1.49
• 1Y Price Target: $22.50
• Price Target Upside: 271.90% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 36 Underperform
• Price Target: ―

Tenax Therapeutics' overall score reflects substantial financial challenges due to an absence of revenue and consistent losses, heavily reliant on equity financing. Technical indicators suggest neutral momentum, but poor financial performance and valuation overshadow any potential stability.

Positive Factors

Patient Adherence

Extraordinary patient adherence in the ongoing Ph3 LEVEL trial with over 95% of randomized patients remaining on therapy.

Phase 3 Trial Success Potential

Management expressed high conviction in the likelihood of success for oral levosimendan’s Phase 3 trial.

Negative Factors

Operating Expenses

TENX reported 4Q24 total operating expenses of $7.3M, above the estimate of $4.7M, driven by higher R&D spending.

Tenax Therapeutics Business Overview & Revenue Model

Company Description

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

How the Company Makes Money

Tenax Therapeutics makes money primarily through the development and commercialization of its pharmaceutical products. The company's revenue model is centered on the successful advancement of its drug candidates through clinical trials, regulatory approvals, and eventual market entry. Revenue streams include potential product sales, licensing agreements, and partnerships with other pharmaceutical companies. Key factors contributing to its earnings include the successful demonstration of clinical efficacy and safety of its drug candidates, strategic alliances with industry partners, and potential collaborations for the distribution and marketing of its products. The company's focus on targeting niche markets with high unmet medical needs may also play a significant role in its revenue generation strategies.

Tenax Therapeutics Financial Statement Overview

Summary

Tenax Therapeutics shows financial instability with zero revenue, negative profitability metrics, and ongoing operational losses. The company's strong equity position and liquidity are primarily due to external financing, which is unsustainable without revenue growth.

Income Statement

The company has consistently reported zero revenue over the years, leading to negative gross profit and net income figures. There is no visible revenue growth trajectory, and profitability metrics such as EBIT and EBITDA are negative, indicating significant losses.

Balance Sheet

The company has a strong equity position with zero total debt and a high equity ratio. However, the lack of revenue and consistent net losses are concerning for long-term sustainability. The cash reserves have been bolstered, which improves liquidity but does not offset the operational losses.

Cash Flow

Operating and free cash flows are negative, reflecting ongoing cash burn. While financing activities have significantly increased cash reserves, this reliance on external financing is not sustainable without revenue generation. The cash flow situation poses a risk if the company cannot turn operations profitable.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-7.57K	-113.33K	-108.98K	-114.75K
EBITDA	-17.58M	-8.23M	-10.93M	-32.36M	-9.74M
Net Income	-17.60M	-7.71M	-11.05M	-32.47M	-9.85M
Balance Sheet
Total Assets	96.69M	11.68M	3.40M	5.99M	6.87M
Cash, Cash Equivalents and Short-Term Investments	94.85M	9.79M	2.12M	5.58M	6.71M
Total Debt	0.00	500.90K	807.89K	290.78K	305.04K
Total Liabilities	4.69M	3.59M	1.91M	1.75M	2.24M
Stockholders Equity	91.99M	8.10M	1.49M	4.24M	4.63M
Cash Flow
Free Cash Flow	-14.81M	-5.90M	-12.02M	-10.86M	-9.28M
Operating Cash Flow	-14.81M	-5.90M	-12.01M	-10.86M	-9.27M
Investing Cash Flow	0.00	2.84K	-2.32K	452.61K	20.11K
Financing Cash Flow	99.87M	13.57M	8.55M	―	10.60M

Tenax Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TENX, the sentiment is Positive. The current price of 6.05 is above the 20-day moving average (MA) of 5.87, above the 50-day MA of 5.89, and above the 200-day MA of 5.73, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 57.65 is Neutral, neither overbought nor oversold. The STOCH value of 71.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TENX.

Tenax Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LGVN	61 Neutral	$25.37M	―	-167.57%	―	127.51%	71.16%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
VYNE	48 Neutral	$22.33M	―	-66.15%	―	43.03%	81.75%
RLMD	41 Neutral	$22.08M	―	-160.26%	―	―	19.21%
TPST	39 Underperform	$26.30M	―	-282.07%	―	―	-220.54%
CLDI	37 Underperform	$26.65M	―	354.78%	―	―	64.19%
TENX	36 Underperform	$25.35M	―	-39.78%	―	―	84.17%

Tenax Therapeutics Corporate Events

Tenax Therapeutics Appoints Interim CFO Thomas McGauley

Tenax Therapeutics, Inc. has appointed Thomas A. McGauley as Interim Chief Financial Officer, effective December 2, 2024. With over 25 years of experience in finance and executive roles, McGauley will lead the company’s financial operations under a consulting agreement with Danforth Advisors. His extensive background includes advisory roles at CBIZ and serving as CFO for various life sciences firms, making him well-suited to guide Tenax’s financial strategy.